March 15th 2024
Cross-sectional study of recent FDA drug approvals evaluated how closely they were aligned with US and global burden of disease.
Bristol Myers Squibb Enhances Early Stage Oncology Clinical Pipeline With Mirati Acquisition
January 24th 2024Mirati’s oncology portfolio includes promising early phase clinical assets such as a potential first-in-class MTA-cooperative PRMT5 inhibitor and a leading KRAS and KRAS enabling program with a pair of candidates in Phase I development.
Micah Lieberman of ClinEco Speaks on the Organization’s Clinical Trials Ecosystem
January 18th 2024In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses what ClinEco is and how the need to create it came about.
BMS Reaches Deal to Codevelop Antibody-Drug Conjugate That Has Shown Promise in Early Trials
December 12th 2023BL-B01D1 is a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate currently being evaluated in the global, multi-center Phase I BL-B01D1-LUNG101 trial in patients with metastatic or unresectable non-small cell lung cancer.
Three Must-Dos for Tracking Research and Development of Monoclonal Antibodies
November 2nd 2023There is an expanding array of potential antibody-based treatment options, such as bispecific or multispecific antibodies, that show promise in addressing conditions such as cancer, engineered antibody fragments, or even antibody-drug conjugates.
An Inside Look into TransCelerate BioPharma
August 21st 2023In this exclusive Q&A with Applied Clinical Trials, Janice Chang, CEO of TransCelerate BioPharma, provides an inside look into her career journey, her work at the company, how the industry has changed in the last 10 years, as well as her thoughts on where the industry should put its efforts in clinical trials.